


PublQoD



Journal of  
Advanced Pharmaceutical  
Technology & Research

An Official Publication of Society of Pharmaceutical Technologists & Researchers

Volume 10, Issue 1, January 2019

[www.japtr.org](http://www.japtr.org)

JAPTR

Indian Society of Pharmaceutical Technologists & Researchers

PharmSoc



## Editorial Board

### Editor-in-Chief

#### Dr. Upendra Nagaich

M.Pharm., Ph.D., FSPER

Professor & Research Coordinator,

Amity Institute of Pharmacy, Amity University,

Noida (U.P.) India

&

National Secretary,

Society of Pharmaceutical Education & Research (SPER), India

### Executive Editors

#### Dr. Paul Wan Sia Heng

Department of Pharmacy,

National University of Singapore,

Singapore

#### Dr. Jaya Pandey

School of Studies in Pharmaceutical Sciences,

Jiwaji University,

Gwalior (M.P.) India

### Associate Editor

#### Dr. Vandana Chaudhary

School of Pharmacy,

Pharmacy Australia Centre of Excellence,

The University of Queensland,

Brisbane, Australia

### Consultant Editor

#### Prof. (Dr.) Laszlo Endrenyi

Professor Emeritus

Department of Pharmacology & Toxicology

University of Toronto, Toronto, Canada

### Section Editors (Alphabetical Order)

#### Dr. Ikoni Ogaji

Dept. of Pharmaceutics & Pharmaceutical Technology,

Faculty of Pharmaceutical Sciences,

University of Jos, Nigeria

#### Dr. Ke Li

J. David Gladstone Institutes,

San Francisco, California, USA

### Editorial Board Members (In Alphabetical Order)

#### Prof. (Dr.) A. N. Kalia

Vice-President, Society of Pharmacognosy,

Professor & Head

I.S.F. College of Pharmacy,


Moga (Punjab), India

#### Dr. Abdul Wahab


### Feedback

[Subscribe](#)

[About the journal](#)

[Most popular articles](#) 

[Join as Reviewer](#) 

[Email alerts](#) 

[Recommend this journal to your library](#) 

Department of Pharmacy  
Kohat University of Science & Technology  
Kohat, KPK, Pakistan

**Prof. (Dr.) Arun Dharmarajan**

Professor  
School of Biomedical Sciences,  
Faculty of Health Sciences,  
Curtin University,  
Perth, Australia

**Prof. (Dr.) Ashoke Kumar Ghosh**

Vice-Chancellor  
IFTM University,  
Moradabad (Uttar Pradesh), India

**Prof. (Dr.) B. Mishra**

Professor & Head  
Department of Pharmaceutics,  
Indian Institute of Technology,  
Banaras Hindu University,  
Varanasi (Uttar Pradesh), India

**Prof. B. G. Shivananda**

Secretary, APTI  
Bangalore (Karnataka), India

**Prof. (Dr.) Bharat B. Aggarwal**

Professor of Cancer Medicine &  
Chief, Cytokine Research Laboratory  
The University of Texas  
Texas, USA

**Dr. Bhaswat Sundar Chakraborty**

Senior VP & Chairman, R&D Core Committee  
Cadila Pharmaceuticals Ltd.  
Ahmedabad (Gujarat), India

**Prof. (Dr.) C. K. Kokate**

National Advisor, Society of Pharmacognosy,  
Vice-Chancellor  
KLE University,  
Belgaum (Karnataka), India

**Prof. (Dr.) Cedric Pearce**

Adjunct Professor  
University of North Carolina  
CEO, Mycosynthetix Inc.  
North Carolina, USA  
[Associate Editor, Journal of Natural Products]

**Prof. (Dr.) Ciddi Veeresham**

Professor  
University College of Pharmaceutical Sciences,  
Kakatiya University,  
Warangal (Andhra Pradesh), India

**Dr. Dâmaris Silveira**

Universidade de Brasília  
Brasília, Brazil

**Prof. (Dr.) Dilipkumar Pal**

Professor  
Dept. of Pharmaceutical Sciences,  
Guru Ghasidas Vishwavidyalaya,  
Bilaspur (Chhattisgarh), India

**Prof. (Dr.) Divakar Goli**

Associate Secretary, IPA  
Secretary, Education Division, IPA  
Professor & Principal  
Acharya & B.M. Reddy College of Pharmacy,  
Bangalore (Karnataka), India

**Prof. (Dr.) G. K. Dash**  
Professor  
Universiti Kuala Lumpur  
Perak Darul Ridzuan, Malaysia

**Prof. (Dr.) H. S. Buttar**  
Adjunct Professor,  
School of Medicine,  
University of Ottawa,  
Ottawa, Canada

**Kaushik Desai**  
Gen. Secretary, IPA  
Immediate Vice President, IPA  
Mumbai (Maharashtra), India

**Prof. (Dr.) Mainul Haque**  
Professor  
Universiti Sultan Zainal Abidin  
Kuala Terengganu, Terengganu, Malaysia

**Dr. Muhammad Akhlaq**  
University of Auckland  
Auckland, New Zealand

**Prof. (Dr.) N. Udupa**  
Professor & Research Director [Health Sciences]  
Manipal University,  
Manipal (Karnataka), India

**Prof. (Dr.) Pornsak Sriamornsak**  
Professor,  
Department of Pharmaceutical Technology &  
Pharmaceutical Biopolymer Group (PBiG),  
Faculty of Pharmacy, Silpakorn University,  
Nakhon Pathom, Thailand

**Dr. Rakesh Kumar Sharma**  
Scientist 'F'  
Director,  
Defence Food Research Laboratory (DFRL),  
Mysuru (Karnataka), India

**Prof. (Dr.) Roop K. Khar**  
Former Professor  
Department of Pharmaceutics,  
Jamia Hamdard (Hamdard University)  
New Delhi, India

**Prof. (Dr.) Roopa Karki**  
Professor & Head  
Department of Pharmaceutics,  
Acharya & BM Reddy College of Pharmacy,  
Bangalore (Karnataka), India

**Prof. (Dr.) S. D. Tonpay**  
Former Professor & Head  
Govt. Gajra Raja Medical College,  
Gwalior (Madhya Pradesh), India

**Prof. (Dr.) S. H. Ansari**  
Professor & Head,  
Department of Pharmacognosy & Phytochemistry,  
Jamia Hamdard (Hamdard University)  
New Delhi, India

**Prof. (Dr.) S. H. Mishra**  
Professor Emeritus  
Faculty of Pharmacy,  
The M. S. University of Baroda,  
Vadodara (Gujarat), India

**Prof. (Dr.) Satish Sardana**  
Immediate Past President, APTI (Haryana)

Director,  
Amity Institute of Pharmacy,  
Amity University,  
Manesar (Haryana), India

**Prof. (Dr.) T. V. Narayana**

President, IPA  
Director  
Vikas Institute of Pharmaceutical Sciences  
Rajahmundry (Andhra Pradesh), India

**Prof. (Dr.) V. K. Dixit**

President, Society of Pharmacognosy,  
Former Professor  
Department of Pharmaceutical Sciences,  
Dr. H. S. Gour University,  
Sagar (M.P.), India

**Prof. (Dr.) Y. K. Agrawal**

Director  
Institute of Research & Development,  
Gujarat Forensic Sciences University,  
Gandhinagar (Gujarat), India

---

[Sitemap](#) | [What's New](#) [Feedback](#) | [Copyright and Disclaimer](#) | [Privacy Notice](#)

© Journal of Advanced Pharmaceutical Technology & Research | Published by Wolters Kluwer - Medknow  
Online since 1<sup>st</sup> November, 2010

[Editorial and Ethics Policies](#)

  [Open Access](#)  [View mobile site](#)

ISSN: Print -2231-4040, Online - 0976-2094



## Table of Contents



**July-September 2021**

Volume 12 | Issue 3

Page Nos. 215-309

Online since Friday, July 16, 2021

Accessed 25,956 times.

### PDF access policy

Journal allows immediate open access to content in HTML + PDF

### EPub access policy

allows EPub access only to users from **INDIA**, developing countries and paid subscribers.

 [View issue as eBook](#)

 [Issue citations](#)

 [Issue statistics](#)

 [RSS](#)

[Show all abstracts](#)

[Show selected abstracts](#)

[Export selected to ▼](#)

[Add to my list](#)

### Feedback

[Subscribe](#)

[Next Issue](#)

[Previous Issue](#)


[Most popular articles](#) 

[Join as Reviewer](#) 

[Email alerts](#) 

[Recommend this journal to your library](#) 

## REVIEW ARTICLE




### Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review p. 215

Subodh Kumar, Manoj Kumar Saurabh, Vikas Maharshi

DOI:10.4103/japtr.JAPTR\_229\_20

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>

## ORIGINAL ARTICLES




### Anticancer, antioxidant, and antibacterial activities of the methanolic extract from *Sphagneticola trilobata* (L.) J. F pruski leaves p. 222

Vivi Mardina, Syafruddin Ilyas, Halimatussakdiah Halimatussakdiah, Tisna Harmawan, Masitta Tanjung, Faridah Yusuf

DOI:10.4103/japtr.JAPTR\_131\_21

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>




### The effect of rice husk nanosilica hydroxyl compound on dentin biomaterialization p. 227

Iffi Aprillia, Endang Suprastiwi, Aryo Megantoro, Luh Putu Trisna, Budi Utami, Sarmayana Yana

DOI:10.4103/japtr.JAPTR\_227\_21

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>




### Antimutagenic activity of nanoparticles of *Rhabdophora pinnata* leaves in mice using micronucleus assay p. 232

Masfria Masfria, Marianne Marianne, Yade Metri Permata, Steven Octavio, Sri Mulyani

DOI:10.4103/japtr.JAPTR\_380\_20

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>




### In silico estrogen receptor alpha antagonist studies and toxicity prediction of *Melia azedarach* leaves bioactive ethyl acetate fraction p. 236

Martha Ervina, Mohammad Rizki Fadhil Pratama, Hadi Poerwono, Juni Ekowati, Retno Widayati, Katsuyoshi Matsunami, Sukardiman

DOI:10.4103/japtr.JAPTR\_198\_21

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>




**Performance and drug deposition of kappa-carrageenan microspheres encapsulating ciprofloxacin HCl: Effect of polymer concentration** p. 242

Dewi Melani Hariyadi, Tutiek Purwanti, Dinda Mauliydia, Cindy Alicia Estherline, Esti Hendradi, Mahardian Rahmadi

DOI:10.4103/japtr.JAPTR\_197\_21

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**Encapsulation mechanism of  $\alpha$ -mangostin by  $\beta$ -cyclodextrin: Methods of molecular docking and molecular dynamics** p. 250

Dian Triwahyuningtyas, Sandra Megantara, Tai Tze Hong, Muhammad Yusuf, Muchtaridi Muchtaridi

DOI:10.4103/japtr.JAPTR\_298\_20

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**Phytochemical screening, antimalarial activities, and genetic relationship of 16 indigenous Thai Asteraceae medicinal plants: A combinatorial approach using phylogeny and ethnobotanical bioprospecting in antimalarial drug discovery** p. 254

Desy Liana, Kanchana Rungsihirunrat

DOI:10.4103/japtr.JAPTR\_238\_21

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**In silico identification of natural products from *Centella asiatica* as severe acute respiratory syndromecoronavirus 2 main protease inhibitor** p. 261

Putu Gita Maya, Widyaswari Mahayasih, Harizal, Herman, Islamudin Ahmad

DOI:10.4103/japtr.JAPTR\_297\_20

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>



**Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma** p. 267

Ishtiaque Ahmad, Zabih Ullah, Mohd Ibrahim Khan, Abdullah Khaloofa Alahmar, Mohd Faiyaz Khan

DOI:10.4103/japtr.JAPTR\_308\_20

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**The color improvement of postdebonding white spot lesions after fluoride and casein phosphopeptide-amorphous calcium phosphate application** p. 274

Haru Setyo Anggani, Putri Arifiani, Erwin Siregar

DOI:10.4103/japtr.JAPTR\_203\_21

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**3,4-dimethoxychalcone novel ultraviolet-A-protection factor in conventional sunscreen cream** p. 279

Erlina Fatmasari, Abdul Karim Zulkarnain, Rina Kuswahyuning

DOI:10.4103/japtr.JAPTR\_89\_21

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**The interaction of alpha-mangostin and its derivatives against main protease enzyme in COVID-19 using in silico methods** p. 285

Syahrul Hidayat, Faisal Maulana Ibrahim, Kelvin Fernando Pratama, Muchtaridi Muchtaridi

DOI:10.4103/japtr.JAPTR\_299\_20

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**Standardization of *Leonurus sibiricus* L. aerial part and capillary electrophoresis quantitative analysis of its leonurine content** p. 291

Manewan Suwatronakorn, Somchai Issaravanich, Chanida Palanuvej, Nijisiri Ruangrungrisi

DOI:10.4103/japtr.JAPTR\_243\_21

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>




**Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease: In silico study** p. 298

Entuy Kurniawan, Dwi Krihariyani

DOI:10.4103/japtr.JAPTR\_222\_21

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1)] [Sword Plugin for Repository]<sup>Beta</sup>



**Characterization and acute oral toxicity of concentrated minerals of Pamekasan Madura seawater** p. 305

Syafika Alaydrus, Abd Kakhar Umar, Sriwidodo Sriwidodo, Ajeng Diantini, Nasrul Wathoni, Riezki Amalia

DOI:10.4103/japtr.JAPTR\_250\_20

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]<sup>Beta</sup>

# In silico estrogen receptor alpha antagonist studies and toxicity prediction of *Melia azedarach* leaves bioactive ethyl acetate fraction

Martha Ervina<sup>1,2</sup>,  
Mohammad Rizki Fadhil Pratama<sup>1,3</sup>,  
Hadi Poerwono<sup>4</sup>, Juni Ekowati<sup>4</sup>,  
Retno Widyowati<sup>4</sup>,  
Katsuyoshi Matsunami<sup>5</sup>,  
Sukardiman<sup>4</sup>

<sup>1</sup>Doctoral Program of Pharmaceutical Sciences, <sup>4</sup>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, <sup>2</sup>Department of Pharmaceutical Biology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, <sup>3</sup>Department of Pharmacy, Faculty of Health Sciences, Universitas Muhammadiyah Palangkaraya, Palangka Raya, Indonesia, <sup>5</sup>Department of Pharmacognosy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Higashihiroshima, Japan

J. Adv. Pharm. Technol. Res.

## ABSTRACT

The estrogen hormone dependent accounts for a major cause in the incidence of women breast cancer. Thus, their receptor, especially the estrogen receptor  $\alpha$  (ER- $\alpha$ ), is becoming a target in endocrine treatment. These ligand-inducible nuclear functions are regulated by an array of phytochemical and synthetic compounds, such as 17  $\beta$ -estradiol and tamoxifen (4-hydroxytamoxifen [4OHT]). The Chinaberry (*Melia azedarach*) leaves are known naturally for relieving internal and external diseases. Previous studies revealed the potency of *Melia's* ethanolic extract and ethyl acetate fractions as anticancer; furthermore, this study aimed to resolve possible ER- $\alpha$  antagonist's mechanism and safety from *M. azedarach* leaves ethyl acetate fraction contents. *Melia's* phytochemical content was analyzed with electrospray ionization liquid chromatography-mass spectrometry, while its ER- $\alpha$  antagonist's potency was investigated by *in silico*. The computational docking was used to 3ERT (a human ER- $\alpha$ -4OHT binding domain complex) with Autodock Vina and related programs. The results presented Energy binding ( $\Delta G$ ) of *Melia's* quercetin 3-O-(2'',6''-digalloyl)- $\beta$ -D-galactopyranoside was similar to 4OHT, and lower than its agonist 17  $\beta$ -estradiol. Furthermore, the toxicity prediction of these compounds were revealed safer than 4OHT. The *Melia's* leaves ethyl acetate fraction, therefore, is a potential pharmacological material for further studies.

**Key words:** Estrogen receptor  $\alpha$ , flavonoids, limonoids, *Melia azedarach*, steroids

## INTRODUCTION

Estrogen, an ovarian steroid hormone, performs by binding to estrogen receptor (ER). The ER antagonists and inhibitors are the most targeted ligands and widely used in breast cancer endocrine therapies, including for

ER-positive metastatic breast cancer patients.<sup>[1]</sup> The ERs are ligand-inducible receptors, such as biosynthesized agonist 17  $\beta$ -estradiol (EST); in addition to antagonist synthetic selective ER modulators, tamoxifen. The latter is often given as an adjuvant treatment for postmenopausal tumor for ER- $\alpha$ -positive individuals and has proved decreasing breast cancer relapse. The ER-tamoxifen complex inhibits the proliferation of the cancer cell, though accompanied with mild-to-severe side effects.<sup>[2]</sup> Furthermore, many ER-positive patients develop intrinsic resistance to hormonal therapies, and this calls for superior alternative treatments.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Ervina M, Pratama MR, Poerwono H, Ekowati J, Widyowati R, Matsunami K, et al. *In silico* estrogen receptor alpha antagonist studies and toxicity prediction of *Melia azedarach* leaves bioactive ethyl acetate fraction. J Adv Pharm Technol Res 2021;12:236-41.

### Address for correspondence:

Prof. Sukardiman,  
Faculty of Pharmacy, Universitas Airlangga, Campus C Unair,  
Jl. Dr. Ir. H. Soekarno Mulyorejo, Surabaya 60115, Indonesia.  
E-mail: martha.pharm@ukwms.ac.id

Submitted: 19-Feb-2021

Revised: 03-Mar-2021

Accepted: 21-Apr-2021

Published: 16-Jul-2021

### Access this article online

#### Quick Response Code:



#### Website:

[www.japtr.org](http://www.japtr.org)

#### DOI:

10.4103/japtr.JAPTR\_198\_21



The selective estrogen ligands were reported to be highly promising targets. These included some analog and phytoestrogen compounds, which bind ERs and exhibit estrogenic or antiestrogenic activities.<sup>[3]</sup> Moreover, their antiproliferative properties could be useful for breast cancer therapies. Genistein isoflavones have similar structures as 17  $\beta$ -estradiol (EST) [Figure 1], which may be responsible for the same active binding sites to ER, thereby producing estrogenic activity. The *Eugenia aquae* leaves dimethylchalcone derivate is reported to not only inhibit MCF-7 human breast cell proliferation but also yield apoptosis through poly-adenosine diphosphate ribose polymerase activations.<sup>[4]</sup>

Some *in silico*, semi-to-synthetic research studies have been reported on phytoconstituents in antiestrogen by, among others, modifying their structures to improve activities and selectivities or to reduce the side effects. Powers and Setzer<sup>[5]</sup> presented the molecular docking of a wide variety of secondary estrogenic metabolites (e.g., flavonoids, isoflavonoids, phenolics, steroids, and triterpenoids) from dietary herbal supplements. They found the phenolics as the strongest to bind ER, while triterpenoids were the weakest among the metabolites.

Chinaberry, *Melia azedarach*, has been used for traditional medicine in some parts of Asia. Various *in vitro* to *in vivo* studies showed *Melia* leaves with ranges of activities.<sup>[6]</sup> The *Melia's* leaves extract has the highest yield compared to other plant parts and classified as safe to use as IC<sub>50</sub> >1000  $\mu$ g/mL against Vero cells.<sup>[7]</sup> Thus, some flavonol glycosides, steroids, and limonoids have been isolated from its extract.<sup>[8]</sup> Moreover, previous researches resulted in highest antioxidant and cytotoxic activities of ethyl acetate fraction. The leaves had potency to some hormonal-dependent cell lines, such as breast cancer MCF7 and T47D.<sup>[8,9]</sup> The wide uses of *Melia* leaves depend, among others, on understanding the possibility mechanisms of the leaves' secondary metabolites to bind with ER- $\alpha$ . Thus, the research will give a scientific base to traditionally uses of the leaves

and supporting to further work on their safety to efficacy as breast cancer adjuvant/co-chemotherapy alternatives. The present study reports findings along these lines.

## MATERIALS AND METHODS

### Extraction and liquid chromatography-mass spectrometry analysis of the extract

The extraction method and the liquid chromatography-mass spectrometry (LC-MS) analysis were followed as described by Ervina *et al.*<sup>[9]</sup> The *M. azedarach* leaves extract was prepared with ethanol 95%, followed with n-hexane and ethyl acetate solvents fractionation. The ethyl acetate was purified with solid-phase extraction (Qasis® HLB solvents) and analyzed with gradient mobile phase step of water, ammonium formic, acetonitrile, and formic acid (0.1%) at 9.2 mL/min for 23 min on EI LC-MS system (Acquity UPLC®-H and Xevo G2-S QToF detector, Waters, Milford, USA), respectively. The chromatogram was processed with MassLynx 4.1 program and data in mass bank (Fiehnlab), Pubchem, or Chempidder.<sup>[10-17]</sup>

### Preparation of ligands

The *Melia's* ligands [Table 1] were prepared with a computer as described in Pratama *et al.*<sup>[18-20]</sup> The HyperChem 7.5 (Hypercube Inc.), OpenBabel 2.4.1 (OpenBabel.org.), and AutoDockTools 1.5.6 and UCSF Chimera 1.13.1 (University of California, San Francisco) program were used.

### Preparation of receptor

The pdb format of human ER- $\alpha$  (3ERT) in complex with 4-hydroxytamoxifen (4OHT) as original ligand was extracted from the protein data bank.<sup>[21,22]</sup> It has 1.90Å resolution and prepared further with AutoDockTools 1.5.6. The prework orientation was done to obtain the lowest RMSD value below 2Å in the grid box parameter.<sup>[23]</sup>

### Validation of docking process

The PyMOL 2.3.1 (Schrodinger LLC.) program was used for proofing the docking processes.<sup>[18]</sup>

### Molecular docking


The docking was proceeded with Autodock Vina 1.1.2.<sup>[18]</sup> and resulted free energies ( $\Delta G$  in a.pdb). The highest ligand affinity was compared to the co-crystal ligand validation result.<sup>[21]</sup> Another parameter was the similarities of amino acid residues and bonding type of their interactions. The Discovery Studio Visualizer v. 19.1.0.18287 was used to visualize them.

### The toxicity prediction of the most potential substances

The SMILES format of the three most potential, quantified, and reference compounds were submitted to GUSAR servers.<sup>[18]</sup>

## RESULTS AND DISCUSSION

As previously obtained, the LC-MS peak spectra were analyzed



**Figure 1:** Typical estrogen receptor alpha antagonist ligands (a) estrogen, (b) tamoxifen, (c) genistein, and (d)  $\beta$ -sitosterol

**Table 1: Liquid chromatography-mass spectrometry analysis of the *Melia azedarach* extract, their energy, original and reference ligands binding to 3ERT**

Percentage relative	Predictive compounds (formula, molecular weight)	Compound ID	SMILES	$\Delta G$ (kcal/mol)
1.42	QOD (C <sub>21</sub> H <sub>20</sub> O <sub>12</sub> , 464.4) <sup>[12]</sup>	12304324	C1=CC(=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O	-7.7
1.31	SLL (C <sub>34</sub> H <sub>44</sub> O <sub>10</sub> , 612.7) <sup>[12]</sup>	15226770	CC=C(C)C(=O)OC1CC(C(C2C1(C(C3(C(C2OC(=O)C)OC4C3=C(C(C4)C5=COC=C5)C)C)CC(=O)OC)C)C=O)O	-7.6
3.27	QOG (C <sub>38</sub> H <sub>34</sub> O <sub>17</sub> , 762.7) <sup>[12]</sup>	5481880	CC1=CC(=CC(=C1)C)C(=O)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4)C3=O)O)O)C5=CC(=C(C=C5)O)O)OC(=O)C6=CC(=C(C=C6)O)O)O	-9.9
1.72	MEB (C <sub>30</sub> H <sub>36</sub> O <sub>11</sub> , 572.6) <sup>[12]</sup>	101965416	CC(=O)OC1CC(C23COC(=O)C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)OC(=O)C)C)O)C)O	-8.1
3.71	DTH (C <sub>30</sub> H <sub>34</sub> O <sub>18</sub> , 682.1745) <sup>[15]</sup>	VF-NPL-QEHF010860	O=C(OCC1OC(OC2=CC(O)=C(O)C=3OC(=C(O)C(=O)C23)C=4C=CC(O)=C(OC)C4)C(OC5OC(C)C(O)C(O)C5O)C(O)C1O)C	-8.0
6.75	1CHM (C <sub>30</sub> H <sub>49</sub> O <sub>18</sub> , 696.7) <sup>[12,13]</sup>	10508889	COC1(OCC23C(CC(O)C4(C)COC(C5OC6(C)C7CC(OC8OC=CC78O)C6(O)C5(C)C12)C34)OC(=O)\C=C/C9=CC=CC=C9)OC(C)=O	-9.4
6.53	TSN (C <sub>30</sub> H <sub>38</sub> O <sub>11</sub> , 574.6) <sup>[12,17]</sup>	9851101	CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)OC(=O)C)C)O)C)O)O	-9.0
1.62	TSN derivatives ([M-H <sub>2</sub> O+H] <sup>+</sup> at 557.4) <sup>[12,17]</sup>	9851101	CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)OC(=O)C)C)O)C)O)O	-9.0
2.50	CCG (C <sub>26</sub> H <sub>32</sub> O <sub>12</sub> , 536.1894) <sup>[15]</sup>	CCMSLIB00000855190	[C@@H]1[C@@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)C(=O)OC[C@@H]1OC(=O)/C=C/C4=CC=CC=C4)O	-8.1
1.14	1SLN (C <sub>34</sub> H <sub>44</sub> O <sub>9</sub> , 596.7) <sup>[12]</sup>	6437066	CC=C(C)C(=O)OC1CC(C2(COC3C2C1(C(C4(C3OC5C4=C(C(C5)C6=COC=C6)C)CC(=O)OC)C)OC(=O)C)OC)O)C5C1(C(C5=O)C6=COC=C6)C)C	-7.9
1.17	MEH/I (C <sub>29</sub> H <sub>38</sub> O <sub>10</sub> , 546.6) <sup>[12]</sup>	101965421	CC(=O)OC1C(=O)C2C(C(C3C24COC(C3(C(C4O)O)C)OC)O)C5C1(C(C5=O)C6=COC=C6)C)C	-8.2
9.39	12HAM-acetyl derivate (C <sub>30</sub> H <sub>40</sub> O <sub>12</sub> ) <sup>[12]</sup>	11970198	CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)O)C)O)C)O)O	-8.6
4.16	12HAM (C <sub>28</sub> H <sub>36</sub> O <sub>10</sub> , 532.6) <sup>[12]</sup>	11970198	CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)O)C)O)C)O)O	-8.6
40.80	EDT (C <sub>35</sub> H <sub>36</sub> O <sub>9</sub> , 620.3924) <sup>[14,15]</sup>	VF-NPL-QEHF023122	O=C(O)C(=CCCC(C)C1CC(O)C2(C)C3CCC4C(C)C(C)C(OC5OCC(O)C(O)C5O)CCC64CC36CC(O)C12)C	-9.1
Original ligand	4OHT (C <sub>26</sub> H <sub>29</sub> NO, 371.5) <sup>[12]</sup>	2733526	CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3	-9.9
Reference ligand	EST (C <sub>18</sub> H <sub>24</sub> O <sub>2</sub> , 272.4) <sup>[12]</sup>	5757	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O	-9.4

TSN: Toosendanin, 1CHM: 1-cinnamoyl-3-hydroxy-11-methoxymeliarcarpinin, QOG: Quercetin 3-O-(2'',6''-digalloyl)- $\beta$ -D-galactopyranoside, DTH: (2R,3S,4S,5R,6S)-3,4-dihydroxy-6-methyl acetate, CCG: Cyclopenta(c)pyran-4-oxy-methyl ester, 12HAM: 12-hydroxyamoorastatin and its acetyl derivate, EDT: (2E)-6-(13,17-dihydroxy)-7-methylhept-2-enoic acid, 4OHT: 4-hydroxytamoxifen, EST: 17 $\beta$ -estradiol

and studied as listed in Table 1. Their higher percentage were steroids, phenolic glycosides, and limonoids, respectively. They were (2E)-6-(13,17-dihydroxy-7---methylhept-2-enoic acid (EDT) (40.80%),<sup>[15]</sup> 12-hydroxyamoorastatin and its acetyl derivate (12HAM, 13.55%),<sup>[12]</sup> 1-cinnamoyl-3-hydroxy-11-methoxymeliarcarpinin (1CHM; 6.75%),<sup>[12]</sup> toosendanin (TSN, 6.53%),<sup>[17]</sup> flavonoid glycoside of quercetin 3-O-(2'',6''-digalloyl)- $\beta$ -D-galactopyranoside (QOG, 3.27%)<sup>[12]</sup> and (2R,3S,4S,5R,6S)-3,4-dihydroxy-6---methyl acetate (DTH, 3.71%) and Cyclopenta[c] pyran-4--oxy-methyl ester (CCG, 2.50%).<sup>[15]</sup> Some of the predictive compounds had

similar aglycone cores compared to the extracts, such as quercetin (Rt 4.80 min), limonoid TSN (Rt 11.72 min), 11-CHM (Rt 11.11 min), Meliarachin H (Rt 15.37 min), 12HAM-acetyl derivate (5.22%, 16.62 min), and steroid of EDT (Rt 19.15 min).

The crystallographic X-ray structure of ER- $\alpha$  complexed with agonist 4OHT. Figure 2 shows similarities in the resolution to the reference parameters (RMSD 1.841–1.9 Å); R-value free and work were 0.262 and 0.229, respectively.<sup>[24]</sup> The molecular docking of the tested ligands is presented in Table 1. The energy binding of QOG (-9.9 kcal/mol) was






complex binding can trigger receptor conformational changes. The ER combines with specific DNA-response element and transcription cellular components, such as co-regulators with derived activation or repression of the lead genes. There are some parts on the ER regions protein named activation functions (AF1 and AF2), which are related to the co-regulators production. Varieties of agonist or antagonist ligands would bind ER. Among the ER residues, the position of helix 12 (H12) will determine agonist or antagonist effects. In the ER-EST complex, H12 lies across the ligand-binding cavity,<sup>[24]</sup> while in the ER-4OHT complex, H12 hinders co-activator recognition grooves by imitating interaction NR box peptides, while the LBD hinders the co-activator. These authors found different LBD ER-4OHT secondary and tertiary conformations compared to ER-DES (diethylstilbestrol, a pure agonist ligand). In 4OHT complexes, the main bonds adopt extended conformations and are different in the formation and position of H12. In 4OHT complexes, H12 is composed of residues 536–544. Furthermore, the complexes occupy the part of the coactivator-binding groove formed by residues 3, 4, and 5 and the turn connecting helices 3 and 4. The ER-ligand bindings on His-524 determine agonist or antagonist of the ligand. His-524 H bonds were observed on EST, but VdW bond on 4OHT and no interactions on the ligands tested. The high affinities in ER- $\alpha$ -QOG complexes indicated the highest similarities amino acid residue to 4OHT as describe in Figure 2b-c and 2f-g.

The GUSAR servers were made to obtain the QSAR/QSPR model based on the ligands data. The results were most in applicable in the model use. The peroral (po) data were observed have higher dose than others [Figure 3a], this means the po route has wider safety margin than others. The ligands have a wide range of LD<sub>50</sub> prediction parameter for compound toxicity [Figure 3a]. All compounds have LD<sub>50</sub> lower than 5000 mg/kg/day. Therefore, they were classified into 4–5 class. This means that the substances may be slightly toxic if swallowed.<sup>[25]</sup>

Moreover, this study provided the potential for adverse effects of most test molecules. The graph describes their IC<sub>50</sub> of the potential adverse effect of the compounds [Figure 3b]. The GUSAR antitarget scheme (in applied model) not only predicts the adverse effect but also provides the potential activity of the compounds. Thirteen receptors were hydroxytryptamine (HT) 1B and 2A, 2C, adrenergic  $\alpha$ 1A, 1B and 2A (ADR), androgen (AND), dopamine (D) D1A, D3, opioid (O)  $\Delta$ ,  $\mu$ ,  $\kappa$  and estrogen (ER). The 5-H2ARA was an example of receptor related to the central nervous system; thus, its antagonist interactions would affect on sickness, emesis, diarrhea, sleeplessness, and anxiety. The ADRA ( $\alpha$ -blockers) may cause disturbances on heart rate, blood tension, nasal congestion, to sleep disturbances and so on. Many adverse effects related to the ER antagonist action are noted such as depression, headache, obesity,



**Figure 3:** Toxicity and some adverse effect predictions of the *Melia azedarach* potential compounds (a) LD<sub>50</sub> parameter, (b) anti target scheme of the compounds, 5 H2ARA: 5 hydroxytryptamine 2A receptor antagonist,  $\alpha$ 1ADRA: Alpha 1a adrenergic receptor antagonist, AOA: Amine oxidase A inhibitor, AND: Androgen receptor antagonist, CA1A: Carbonic anhydrase I activator, D1ARA: D(1A) dopamine receptor antagonist, O dRA: Delta type opioid receptor antagonist, ER: Estrogen receptor alpha antagonist, Na Cl GABA1A: Sodium and chloride dependent GABA transporter 1 antagonist, Na dDtA: Sodium dependent serotonin transporter antagonist

and hot flashes. Other compounds' interactions were to enzymes (AOIA) and transporters (serotonin, GABA, and dopamine) [Figure 3b, respectively]. The main adverse effects of AOIA inhibitors are blood pressure instability to hepatotoxicity, while severe anaphylaxis to bone marrow suppression would have been caused by CA1A. The GABA and dopamine transporter blockers were caused acute respiratory distress syndrome. Among the tested ligands, it was 4OHT showed 17 cell antitargets, while the sequences from the least were the EDT (5), QOG (8), and 1CHM (13).

These findings implied that the EDT is relatively safer compare to others. The side effects of the QOG flavonoid glycoside may occur on hormone and neurotransmitter signaling disorders due to binding with ADR, while 4OHT and EST may result in nervous system and fertility disorder because they interfere with AOA, AND and ER [Figure 3b].<sup>[26,27]</sup> These findings highlighted the molecular potency, interaction mechanisms, and safety prediction of *M. azedarach* phytochemicals.

## CONCLUSION

The *Melia's* quercetin-3-O-digalloyl- $\beta$ -D-galactopyranoside, limonoid, and steroid possessed low binding energy and measured inhibitory effects (antagonists) interactions on 3ERT. These compounds were found safer than 4OHT.

## Acknowledgments

Republik Indonesia Kemenristekdikti PKPI 2019.

## Financial support and sponsorship

Republik Indonesia Kemenristekdikti via BPPDN 2017-2021, and PDD 2020-2021.



**Conflicts of interest**


There are no conflicts of interest.

**REFERENCES**

- Sharma D, Kumar S, Narasimhan B. Estrogen alpha receptor antagonists for the treatment of breast cancer: A review. *Chem Cent J* 2018;12:107.
- Chang M. Tamoxifen resistance in breast cancer. *Biomol Ther (Seoul)* 2012;20:256-67.
- Farzaneh S, Zarghi A. Estrogen receptor ligands: A review (2013-2015). *Sci Pharm* 2016;84:409-27.
- Subarnas A, Diantini A, Abdulah R, Zuhrotun A, Hadisaputri YE, Puspitasari IM, et al. Apoptosis induced in MCF-7 human breast cancer cells by 20,40-dihydroxy-6-methoxy-3,5-dimethylchalcone isolated from *Eugenia aquea* Burm f. leaves. *Oncol Lett* 2015;9:2303-6.
- Powers CN, Setzer WN. A molecular docking study of phytochemical estrogen mimics from dietary herbal supplements. *In Silico Pharmacol* 2015;3:4.
- Ervina M, Sukardiman. A review: *Melia azedarach* L. as a potent anticancer drug. *Pharmacogn Rev* 2018;12:94-102.
- Srinivasan V, Panneerselvam R, Gunasekaran S, Palani S. Nephro-protective activity of ethanolic extract of *Melia azadirachta* against H<sub>2</sub>O<sub>2</sub> induced toxicity in *Vero* cell line. *Int J Appl Biol Pharm Technol* 2015;6:44-9.
- Jafari M, Saeidnia S, Hajimehdipoor S, Ardekani H, Faramarzi MR, Hadjiakhoondi MA, et al. Cytotoxic evaluation of *Melia azedarach* in comparison with *Azadirachta indica* and its phytochemical investigation. *DARU J Pharm Sci* 2013;2:37-44.
- Ervina M, Poerwono H, Widyowati R, Matsunami K, Sukardiman. Bio-selective hormonal breast cancer cytotoxic and antioxidant potencies of *Melia azedarach* L. wild type leaves. *Biotechnol Rep (Amst)* 2020;25:e00437.
- Little JL, Williams AJ, Pshenichnov A, Tkachenko V. Identification of "Known Unknowns" utilizing accurate mass data and ChemSpider. *J Am Soc Mass Spectrom* 2012;23:179Y185.
- Blaženović I, Kind T, Ji J, Fiehn O. Software tools and approaches for compound identification of LC-MS/MS data in metabolomics. *Metabolites* 2018;8:31.
- PubChem, US National Library of Medicine, National Centre for Biotechnology Information; 2020. Available from: <https://pubchem.ncbi.nlm.nih.gov/>. [Last accessed on 2021 Jan 21].
- Chemspider, Royal Society of Chemistry; 2020. Available from: <http://www.chemspider.com/>. [Last accessed on 2021 Jan 21].
- Mitaine-Offer AC, Marouf A, Hanquet B, Birlirakis N, Lacaille-Dubois MA. Two triterpene saponins from *Achyranthes bidentata*. *Chem Pharm Bull (Tokyo)* 2001;49:1492-4.
- Mona-Mass bank of North America; 2020. Available from: <https://mona.fiehnlab.ucdavis.edu/spectra/display/>. [Last accessed on 2021 Jan 21].
- Tada K, Takido M, Kitanaka S. Limonoids from fruit of *Melia toosendan* and their cytotoxic activity. *Phytochemistry* 1999;51:787-91.
- Ong ES, Ong CN. Qualitative and quantitative analysis of toosendanin in *Melia toosendan* Sieb. Et Zucc (*Meliaceae*) with liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007;21:589-98.
- Pratama MR, Poerwono H, Siswodiharjo S. ADMET properties of novel 5-O-benzoylpinostrubin derivatives. *J Basic Clin Physiol Pharmacol* 2019;30:20190251.
- O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: An open chemical toolbox. *J Cheminform* 2011;3:33.
- Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. *Nat Protoc* 2016;11:905-19.
- Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, et al. The protein data bank. *Acta Crystallogr D Biol Crystallogr* 2002;58:899-907.
- Protein Data Bank; 2020. Available from: <https://www.rcsb.org/structure/6lu7>. [Last accessed on 2021 Jan 21].
- Morris GM, Huey R, Lindstrom W, Sanner M, Belew RK, Goodsell DS, et al. Autodock4 and Autodocktools4: Automated docking with selective receptor flexibility. *J Comput Chem* 2009;30:2785-91.
- Kong EH, Pike AC, Hubbard RE. Structure and mechanism of the oestrogen receptor. *Biochem Soc Trans* 2003;31:56-9.
- Zakharov AV, Lagunin AA, Filimonov DA, Poroikov VV. Quantitative prediction of antitarget interaction profiles for chemical compounds. *Chem Res Toxicol* 2012;25:2378-85.
- Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, et al. Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. *J Med Chem* 2012;55:2287-300.
- Wahl J, Smieško M. Endocrine disruption at the androgen receptor: Employing molecular dynamics and docking for improved virtual screening and toxicity prediction. *Int J Mol Sci* 2018;19:1784.


## Journal of Advanced Pharmaceutical Technology and Research

<b>COUNTRY</b> India  	<b>SUBJECT AREA AND CATEGORY</b> Pharmacology, Toxicology and Pharmaceutics ↳ Pharmaceutical Science	<b>PUBLISHER</b> Wolters Kluwer Medknow Publications	<b>H-INDEX</b> <h1>38</h1>
<b>PUBLICATION TYPE</b> Journals	<b>ISSN</b> 01105558, 09762094	<b>COVERAGE</b> 2010-2021	<b>INFORMATION</b> <a href="#">Homepage</a> <a href="#">How to publish in this journal</a> <a href="mailto:editor@japtr.org">editor@japtr.org</a>



● SJR

2013	0.503
2014	0.759
2015	0.475
2016	0.485
2017	0.309
2018	0.326
2019	0.267
2020	0.325
2021	0.310





# Source details

## Journal of Advanced Pharmaceutical Technology and Research

Open Access ⓘ

Scopus coverage years: from 2010 to Present

Publisher: Wolters Kluwer Health

ISSN: 2231-4040 E-ISSN: 0976-2094

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science

Source type: Journal

CiteScore 2021

2.3 ⓘ

SJR 2021

0.310 ⓘ

SNIP 2021

0.823 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### Improved CiteScore methodology ⓘ

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▾

$$2.3 = \frac{396 \text{ Citations 2018 - 2021}}{173 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$1.9 = \frac{606 \text{ Citations to date}}{325 \text{ Documents to date}}$$

Last updated on 05 March, 2023 • Updated monthly

## CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#91/171	47th
Pharmaceutical Science		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site &](#)